3/8/2019 | HY | Market Commentary: Morning Commentary: High yield feels heavy heading into weekend; new Digicel bonds gain
|
11/15/2018 | BK | Market Commentary: LMBE, Valeant, Chef’s Warehouse break; Openlink, MSX, GPS updated; Element accelerated
|
11/15/2018 | CLHY | Market Commentary: LMBE, Valeant, Chef’s Warehouse break; Openlink, MSX, GPS updated; Element accelerated
|
11/14/2018 | CLHY | Market Commentary: LifePoint, Infrastructure & Energy, Concrete Pumping break; Valeant, Openlink revise deals
|
11/14/2018 | BK | Market Commentary: LifePoint, Infrastructure & Energy, Concrete Pumping break; Valeant, Openlink revise deals
|
11/14/2018 | BK | Valeant cuts spread on $1.5 billion term loan to Libor plus 275 bps
|
11/13/2018 | BK | Market Commentary: LifePoint, Valeant revise loans; Applied Systems firms terms; multiple deals come to market
|
11/13/2018 | CLHY | Market Commentary: LifePoint, Valeant revise; Applied Systems firms terms; multiple deals come to market
|
11/13/2018 | BKCAHY | Valeant lifts term loan to $1.5 billion, cancels potential bond deal
|
11/8/2018 | BK | Market Commentary: AssetMark, PetVet break; WeddingWire, TRC tweak loans; multiple deals set talk with launch
|
11/8/2018 | CLHY | Market Commentary: AssetMark, PetVet break; WeddingWire, TRC tweak loans; multiple deals set talk with launch
|
11/8/2018 | BK | Valeant Pharmaceuticals talks $750 million term loan at 99-99.5 OID
|
11/8/2018 | BKCADDHY | Fitch rates Valeant loan BB-
|
11/7/2018 | CAHY | Valeant mulls new junk bond issue to help fund tender for 7½% notes
|
11/7/2018 | BK | Market Commentary: PolyOne frees to trade atop OID; Information Resources, AssetMark, PetVet revise deals
|
11/7/2018 | CLHY | Market Commentary: PolyOne frees to trade atop OID; Information Resources, AssetMark, PetVet revise deals
|
11/7/2018 | BK | Valeant Pharmaceuticals to launch $750 million term loan on Thursday
|
5/17/2018 | BKCADDHY | Fitch rates Valeant facility BB-, notes B-
|
5/15/2018 | BKCAHY | Moody’s rates Valeant loans Ba3
|
5/8/2018 | BKCVDDEMIGPV | Market Commentary: Primary quiet; Gaming & Leisure active; Dish volatile; Sanchez Energy drops, Valeant gains
|
5/8/2018 | HY | Market Commentary: Primary quiet; Gaming & Leisure active; Dish bonds volatile; Sanchez Energy drops, Valeant gains on earnings
|
3/12/2018 | BKCAHY | S&P gives B- to Valeant notes
|
10/20/2016 | HY | Market Commentary: Energy sees modest moves as oil slumps; Valeant actively traded without much movement
|
10/20/2016 | DD | Market Commentary: Energy sees modest moves as oil slumps; Valeant active without much movement; non-actives trade again
|
3/15/2016 | DD | Market Commentary: Linn Energy trading flat after missed coupon payment; Energy XXI also skips coupon; Valeant down
|
2/11/2016 | BK | Market Commentary: Bids on three BWICs come due; Alpha Media takes second crack at first-lien loan syndication
|
9/21/2012 | BKCVHY | Moody's: Valeant unaffected
|
9/21/2012 | CA | Moody's: Valeant unaffected by bond upsizing
|
9/20/2012 | CAHY | New Issue: Valeant Pharmaceuticals prices restructured $2.25 billion two-part deal
|
9/20/2012 | HY | Market Commentary: Valeant, Rockwood mega-deals pace nearly $6 billion session; funds post $1.36 billion gain
|
9/4/2012 | HY | Market Commentary: Axle, Rock-Tenn price; $3 billion more slates as post- holiday primary revives; ATP slide deepens
|
7/6/2011 | BK | Valeant gets $200 million 18-month revolver at Libor plus 300 bps
|
5/3/2011 | BKCACVHY | Moody's confirms Valeant
|
3/9/2011 | BKCACVHY | S&P rates Valeant notes BB-
|
3/4/2011 | CA | Market Commentary: Ontario sells C$600 million add-on; Skylink markets notes; municipal deals to pick up
|
3/3/2011 | CA | Market Commentary: Valeant Pharmaceuticals wraps deal; Skylink starts roadshow; Vermilion 6.5% notes stronger
|
3/3/2011 | CAHY | New Issue: Valeant Pharmaceuticals sells $1.5 billion senior notes in two parts
|
3/3/2011 | HY | Market Commentary: Valeant, MEMC, Jo-Ann Stores price; new Jo-Ann, Perry Ellis hot, Jones is not; funds gain
|
3/2/2011 | BKCACVHY | Moody's cuts Valeant to stable, rates notes Ba3
|
3/2/2011 | BKCACVHY | S&P rates Valeant notes BB-
|
3/2/2011 | HY | Market Commentary: SandRidge, Windstream lead active drive-by parade; secondary softer but NewPage busy, better
|
3/1/2011 | BK | Valeant Pharmaceuticals to pay down term loan A, cancel revolver
|
3/1/2011 | CAHY | Valeant Pharmaceuticals launches $1.5 billion notes offering
|
3/1/2011 | CVLM | Valeant Pharmaceuticals plans to redeem 4% convertibles due 2013
|
2/7/2011 | BKCACVHY | S&P assigns Valeant loan BB+, notes BB-
|
2/3/2011 | BKCACVHY | S&P rates Valeant notes BB-
|
2/3/2011 | CA | Market Commentary: Royal Bank of Canada, Vermilion, Valeant fill appetites; interest keen in oil, gas bonds
|
2/3/2011 | CAHY | New Issue: Valeant Pharmaceuticals prices $650 million 10.5-year notes at par to yield 63/4%
|
2/3/2011 | HY | Market Commentary: Valeant, Denbury drive-bys pace primary; new Ford busy; OPTI Canada rebounds; funds gain
|
2/3/2011 | BKCACVHY | Moody's rates Valeant notes B1
|
11/23/2010 | CA | Market Commentary: Glacier Credit Card, AltaGas, Canadian Western Bank flood market; Paramount to start roadshow
|
11/23/2010 | HY | Market Commentary: Rain CII, Brightstar, American Reprographics price, but Performance Foods, Spencer drop out
|
11/22/2010 | CA | Market Commentary: Potash sells $1 billion two-part U.S. deal; BAM Split brings preferreds; Valeant widens
|
11/22/2010 | HY | Market Commentary: Northern Tier, ClubCorp. price, move up; Ship Finance pulls deal, Murray restructures
|
11/19/2010 | CA | Market Commentary: Fortis week's third utility deal; Quebec sells C$500 million; Cara roadshow gains interest
|
11/19/2010 | HY | Market Commentary: Petco, upsized Paetec price, both rise to close out $10 billion week; secondary slide resumes
|
11/18/2010 | CA | Market Commentary: Capital Desjardins, Newalta, Valeant Pharmaceuticals lift high-grade, junk bond markets
|
11/18/2010 | CAHY | New Issue: Valeant Pharmaceuticals sells upsized $1 billion 6 7/8% eight-year notes to yield 7%
|
11/18/2010 | CV | Moody's rates Valeant notes B1
|
11/18/2010 | HY | Market Commentary: Wind, Valeant megadeals lead $4 billion day; First Data up, GM down; funds lose $723 million
|
10/28/2010 | HYLM | Valeant Pharmaceuticals redeems $765 million in 7 5/8%, 8 3/8% notes
|
9/27/2010 | HYLM | Valeant defeases 7 5/8% and 8 3/8% notes; redemption set for Oct. 27
|
9/23/2010 | BK | Market Commentary: DineEquity, Nalco, GenTek, others set price talk; Graham makes draw for acquisition close
|
9/22/2010 | BKCVHY | S&P revises Valeant notes to BB-
|
9/9/2010 | CVHY | S&P rates Valeant loan BB+
|
9/8/2010 | CV | Moody's rates Valeant Ba3
|
9/8/2010 | HY | Moody's rates Valeant loans Ba1, notes B1
|
6/22/2010 | CV | Market Commentary: Teva series Ds active in trade; Transocean ends lower; Biovail, Lincare better; PPL adds
|
6/21/2010 | CV | Market Commentary: Biovail gains on merger with Valeant; Amgen up on competitor's drug safety; PPL on tap
|
6/21/2010 | CVHY | Moody's: Valeant unchanged
|
6/21/2010 | HYLM | Valeant to refinance 7 5/8%, 8 3/8% notes as part of Biovail merger
|
5/26/2010 | CV | UAL convertibles, other in-the-money paper could see premium expansion in down market: Epstein
|
4/6/2010 | CVHY | S&P lifts Valeant, rates notes BB-
|
4/6/2010 | CVHY | Moody's assigns Valeant notes Ba3
|
4/6/2010 | HY | New Issue: Valeant sells upsized $400 million 7 5/8% 10-year senior notes at par
|
4/6/2010 | HY | Market Commentary: Ford Credit sells $1.75 billion, existing bonds slip; Valeant prices; GM dips; Six Flags up
|
3/30/2010 | CVHY | Valeant may buy back up to $500 million more notes, convertible debt
|
1/8/2010 | BWCVHY | Valeant CEO says recent acquisitions position company for growth
|
9/23/2009 | BWCVHYSS | Valeant Pharmaceuticals narrows focus, looks for double-digit growth
|
8/24/2009 | CV | Market Commentary: AMD finds buyers, gains on Citi upgrade; SanDisk adds; Valeant holds in after failed trial
|
8/14/2009 | CV | Valeant Pharmaceuticals to pay cash, issue warrants in exchange for $55.93 million 3% convertibles
|
7/23/2009 | SS | ValueAct reports 21.5% ownership interest in Valeant Pharmaceuticals
|
6/17/2009 | SS | ValueAct reports 20.3% ownership interest in Valeant Pharmaceuticals
|
6/4/2009 | HY | Market Commentary: Upsized Mariner, U.S. Oncology price; junk tone softer; Michaels up on results; funds jump $918 million
|
6/3/2009 | HY | New Issue: Valeant upsizes to $365 million, prices 8 3/8% seven-year notes at 96.797 to yield 9%
|
6/3/2009 | HY | Market Commentary: Upsized Domtar, Valeant price deals, Valeant moves up; junk surge slows; Ford keeps firming
|
5/29/2009 | CVHY | Moody's rates Valeant B1, notes Ba3
|
5/29/2009 | HY | Market Commentary: Market improves, new issues remain the focus; GM bonds active, weaker; Rite Aid ends mixed
|
5/28/2009 | CVHY | S&P: Valeant view positive
|
5/28/2009 | HY | Market Commentary: Ford, Cricket mega-deals lead primary; GM bonds up on revised debt-swap plan; funds see 11th gain, $623 million
|
5/28/2009 | HY | Valeant to start roadshow Monday for $300 million seven-year notes
|
5/28/2009 | CV | Valeant ups repurchase program for convertibles, stock to $500 million
|
5/18/2009 | CV | Market Commentary: Convertibles secondary market mostly quiet as equities surge; Covanta, AngloGold to price
|
5/18/2009 | SS | ValueAct reports 19.3% ownership interest in Valeant Pharmaceuticals
|
5/15/2009 | SS | Valeant Pharmaceuticals investor ValueAct buys 2.5 million shares
|
1/2/2009 | SS | Market Commentary: Zell homes in on Starwood Hotels; Dynegy quits joint venture
|
12/10/2008 | CVHY | Valeant redeems $33 million of convertibles in November
|
12/2/2008 | SS | Valeant Pharmaceuticals shareholder ValueAct reports 16.2% ownership interest
|
7/31/2008 | CVHY | S&P ups Valeant
|
6/20/2008 | HY | Valeant calls all $300 million outstanding 7% notes
|
6/11/2007 | CVHY | S&P: Valeant unaffected
|
2/1/2007 | CVHY | S&P affirms Valeant
|
1/24/2007 | CVHY | Moody's confirms Valeant
|
12/18/2006 | CVHY | Moody's drops Valeant
|
12/14/2006 | CVDD | Valeant Pharmaceuticals receives default notice on 3% convertible notes due 2010
|
11/16/2006 | BTCVHY | S&P drops Valeant Pharmaceuticals
|
11/2/2006 | BT | Valeant releases preliminary third-quarter results as stock option practices reviewed
|
10/24/2006 | BTCVHY | S&P puts Valeant on watch
|
10/24/2006 | BTCVHY | Moody's may downgrade Valeant
|
10/23/2006 | BTCVDDHY | Valeant Pharmaceuticals 10-Q filing delay could prompt high-yield, convertible notes defaults
|
9/21/2006 | BKBTCVHY | Moody's revises ratings for nine U.S. pharma companies
|
9/12/2006 | BT | Valeant plans to grow base business by 5%-10% per year, save up to $30 million in 2006
|
9/12/2006 | BT | Valeant: Viser 2 fails efficacy endpoint in hepatitis C study
|
9/11/2006 | BT | Valeant: SEC conducting inquiry into Ribapharm public offering
|
8/17/2006 | BT | Valeant announces U.S. availability of Cesamet; post-marketing clinical trial to start soon
|
8/3/2006 | BT | Valeant second-quarter revenues increase 12% to $230.2 million
|
7/11/2006 | BT | Valeant Pharmaceuticals must pay $2.4 million in damages to Caleel + Hayden
|
6/29/2006 | BT | Valeant expects cost savings between $20 million and $30 million this year
|
6/15/2006 | BT | Valeant receives FDA approval of Zelapar for patients with Parkinson's disease
|
5/23/2006 | BKBTHY | S&P lowers Valeant Pharmaceutical view to negative
|
5/18/2006 | BT | Valeant sells manufacturing facility in Poland
|
5/16/2006 | BT | FDA approves Valeant's cannabinoid Cesamet for chemotherapy-induced nausea, vomiting
|
4/12/2006 | BT | Metabasis' partner Valeant to out-license pradefovir for hepatitis B
|
4/4/2006 | BT | Market Commentary: Valeant up on restructuring; Nabi gains; Avanir rises on drug filing; Enzon higher; ViroPharma eyed
|
4/3/2006 | BT | Valeant plans restructuring to reduce costs, improve earnings, focus on late-stage products
|
3/24/2006 | BT | Market Commentary: BioMarin shares, new bonds gain; Cephalon loses 13%; Idenix falls 28%; King slips; Encysive declines
|
3/23/2006 | BTCVHY | Moody's affirms Valeant Pharmaceuticals
|
3/21/2006 | BT | Valeant's Viramidine hits safety endpoint, fails to meet efficacy endpoint during phase 3 hepatitis C study
|
3/16/2006 | BT | Valeant's pradefovir reduces hepatitis B viral load during phase 2 study
|
3/8/2006 | BT | Valeant Pharmaceuticals settles Galenika dispute
|
2/22/2006 | BT | FDA approves less-restrictive labeling for Valeant's Parkinson's disease drug Tasmar
|
12/30/2005 | BT | FDA says Valeant's Cesamet 'nonapprovable' due to concerns about adverse events
|
11/29/2005 | BT | Market Commentary: InterMune, Valeant slip; Voyager IPO chatted up; Encysive higher; Dendreon, ViroPharma decline
|
11/29/2005 | BTCVHY | S&P: Valeant unaffected
|
11/28/2005 | BT | Valeant buys rights to Infergen from InterMune
|
11/15/2005 | BT | Valeant says phase 2 trials indicate pradefovir mesylate more effective for hepatitis B than Hepsera
|
11/3/2005 | BT | Par and Valeant to co-promote Cesamet for chemotherapy-induced nausea and vomiting
|
9/29/2005 | BTCVHY | S&P lifts Valeant view to stable
|
2/2/2005 | CVHY | S&P affirms Valeant Pharmaceuticals
|
10/19/2004 | CV | Merrill Lynch recommends Valeant 4% convertible on attractive price, positive view on stock
|
6/21/2004 | CV | Valeant calls $236.6 million 61/2% convertibles
|
2/13/2004 | CVHY | S&P: Valeant unaffected
|
12/10/2003 | HY | Market Commentary: Blue Ridge deal, downsized THL/Simmons price; Collins & Aikman speeds upward
|
12/9/2003 | HY | Valeant Pharmaceuticals upsizes eight-year notes to $300 million, yield 7%
|
12/9/2003 | HY | Market Commentary: Valeant, Hanover, Equinox price deals, stilling secondary
|
12/5/2003 | HY | Market Commentary: iStar, Sweetheart price deals, NRG mega-deal ahead; Qwest up on upsized tender offer
|
12/5/2003 | HY | Valeant Pharmaceuticals $275 million eight-year notes talked at 7%-71/4%
|
12/4/2003 | CVHY | Moody's rates Valeant senior notes B1
|
12/2/2003 | HY | S&P rates new Valeant notes BB-
|
11/26/2003 | HY | Market Commentary: Waterford Wedgwood deal prices; secondary falls silent ahead of break
|
11/25/2003 | CVHY | S&P rates new Valeant notes BB-
|
11/25/2003 | HY | Market Commentary: GNC, TVN, Jostens price deals; Dana bonds better after takeover try falters
|
11/25/2003 | HY | Valeant to start roadshow Monday for $275 million eight-year notes
|
11/19/2003 | CV | Valeant greenshoe exercised, raising convertibles to $480 million
|
11/14/2003 | CV | Market Commentary: Valeant 3s end at 103.75 bid, 4s end at 104.75 bid; Amgen converts resist slide with stock
|
11/14/2003 | CV | New Issue: Valeant sells $400 million convertibles; Tranche A at 3%, up 40%; Tranche B at 4%, up 40%
|
11/13/2003 | CV | Valeant launches $400 million convertibles in 6.75-year, 10-year tranches
|
11/13/2003 | CV | Market Commentary: Both Valeant tranches bid up 2 points in gray, Radisys up 2.5; Casual Male adds 2.5
|
11/13/2003 | CVHY | S&P rates Valeant convertibles B
|